Cannabis Use Disorder Treatment Market is segmented by Type (Marijuana, Tobacco/Nicotine and Vaping, Alcohol, Synthetic Cannabinoids, Others), Treatment (Counselling & Behavioral Therapy, Detoxification, Medication, Support Group), End User (Rehabilitation Centers, Hospitals and Clinics, Others), and Region. Forecast for 2026 to 2036.
The cannabis use disorder treatment market encompasses pharmaceutical products, diagnostic tools, and therapeutic interventions that address the core requirements of type applications across treatment, and related end-use categories. The market covers products segmented by type, treatment, end user, delivery channel, spanning the forecast period from 2026 to 2036.
Market scope encompasses all commercially relevant cannabis use disorder treatment products categorized by Type, Treatment, End User, Delivery Channel. The revenue scope covers the period from 2026 to 2036 across North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
The scope does not include over-the-counter supplements without regulatory approval, general wellness products not specific to the indicated condition, or devices and equipment used solely for diagnostic purposes without therapeutic function.
The market for cannabis use disorder therapy is growing steadily thanks to structural demand drivers that are unlikely to change over the course of the forecast period. Evidence-based treatment protocols are receiving more funding from healthcare systems around the world, and payer systems are starting to cover a wider range of therapy alternatives in this category.
At 44.6%, marijuana has the most share of the type sector. This is a reflection of physician prescribing practices and established clinical standards that support this therapeutic approach as a first-line intervention.
Structural growth variables include policy changes pertaining to treatment recommendations, antimicrobial stewardship, and reimbursement systems. The addressable market for compliant therapeutic items grows as regulatory agencies in the USA, EU, and Asia-Pacific update clinical standards.
The market for cannabis use disorder treatment is organized across product, end-use, and channel dimensions. Segmentation by type includes Marijuana, Tobacco/Nicotine and Vaping, Alcohol, Synthetic Cannabinoids, Others. By treatment, the market includes Counselling & Behavioral Therapy, Detoxification, Medication, Support Group.
It is anticipated that marijuana will make up 44.6% of the type category in 2026. This therapeutic category is the default option in the majority of treatment protocols due to its well-established clinical data, widespread regulatory approval, and physician familiarity.
Newer formulation techniques are anticipated to enhance patient compliance and clinical outcomes in this segment as treatment methods continue to change. Volume growth is probably going to be sustained by the development of treatment availability in emerging markets.
Counselling & Behavioral Therapy accounts for 39.8% of the treatment segment. This channel benefits from concentrated purchasing authority, standardized procurement processes, and the clinical infrastructure needed to support treatment administration.
The cannabis use disorder treatment market is shaped by a balance of demand-side growth factors and supply-side constraints. Clinical evidence continues to support market expansion, while cost management and access challenges moderate the pace of adoption in certain geographies.
Demand reflects the ongoing evolution of clinical guidelines toward evidence-based treatment selection. As regulatory bodies update standard-of-care protocols, the addressable market for compliant products expands.
Adoption is moderated by the cost differential between newer therapeutic options and established generic alternatives. Reimbursement dynamics and formulary inclusion decisions remain key determinants of market penetration.
Growth reflects increasing healthcare infrastructure investment across Asia, Latin America, and the Middle East. As hospital capacity and specialist access improve, treatment adoption rates in these regions are expected to converge toward developed market levels.
.webp "Top Country Growth Comparison — Cannabis Use Disorder Treatment Market CAGR (2026–2036)")
| Country | CAGR |
|---|---|
| USA | 5.1% |
| UK | 4.5% |
| EU | 4.8% |
| Japan | 3.5% |
| South Korea | 4.2% |
The global cannabis use disorder treatment market is expected to grow at a rate of 4.7% per year from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.
The USA will grow by 5.1% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.
The UK will grow by 4.5% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.
The European Union will grow by 4.8% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.
Japan will grow by 3.5% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.
South Korea will grow by 4.2% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.
Indivior PLC leads the market through a combination of clinical evidence, regulatory approvals, and distribution access across major healthcare systems. The competitive landscape is fragmented, with established players competing on clinical outcomes, pricing, and market access.
Barriers to entry include regulatory approval timelines, clinical trial investment requirements, and established physician prescribing relationships. Strategic priorities include expanding treatment access, strengthening clinical evidence, and improving cost competitiveness.
Key global companies leading the cannabis use disorder treatment market include:
| Company | Product Portfolio | Clinical Evidence | Distribution Reach | Geographic Footprint |
|---|---|---|---|---|
| Indivior PLC | High | Strong | Strong | Global |
| Zynerba Pharmaceuticals | High | Strong | Strong | Global |
| Pfizer Inc. | High | Strong | Strong | Global |
| GW Pharmaceuticals (Jazz Pharmaceuticals) | Medium | Medium | Moderate | Regional |
| Adial Pharmaceuticals | Medium | Medium | Moderate | Regional |
| Omeros Corporation | Medium | Medium | Moderate | Regional |
| BioCorRx Inc. | Medium | Medium | Low | Emerging |
| Alkermes PLC | Medium | Medium | Low | Emerging |
| Pear Therapeutics | Medium | Medium | Low | Emerging |
| Braeburn Pharmaceuticals | Medium | Medium | Low | Emerging |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Cannabis Use Disorder Treatment Market
Major Global Players
Emerging Players/Startups
| Quantitative Units | USD 1.78 billion to USD 2.82 billion, at a CAGR of 4.7% |
|---|---|
| Market Definition | The cannabis use disorder treatment market encompasses pharmaceutical products and therapeutic solutions across type, treatment, end user, delivery channel categories. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, UK, EU, Japan, South Korea, 30 plus countries |
| Key Companies Profiled | Indivior PLC, Zynerba Pharmaceuticals, Pfizer Inc., GW Pharmaceuticals (Jazz Pharmaceuticals), Adial Pharmaceuticals, Omeros Corporation, BioCorRx Inc., Alkermes PLC, Pear Therapeutics, Braeburn Pharmaceuticals |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
What is the global market demand for Cannabis Use Disorder Treatment in 2026?
In 2026, the global market for cannabis use disorder treatment is expected to be worth USD 1.78 billion.
How big will the market for Cannabis Use Disorder Treatment be in 2036?
By 2036, the market for cannabis use disorder treatment is expected to be worth USD 2.82 billion.
How much do you think demand for Cannabis Use Disorder Treatment will grow between 2026 and 2036?
Between 2026 and 2036, the demand for cannabis use disorder treatment is expected to grow at a CAGR of 4.7%.
Which Type segment is likely to be the best seller in the world by 2026?
Marijuana is expected to account for 44.6% of the market in 2026, reflecting its established position in clinical treatment protocols.
What is causing demand to rise in USA?
USA will grow at a rate of 5.1% per year through 2036, supported by advanced healthcare infrastructure and expanding treatment access.
What is causing demand to rise in EU?
EU will grow at a rate of 4.8% per year through 2036, supported by expanding healthcare investment and regulatory modernization.
What does this report mean by "Cannabis Use Disorder Treatment Market definition"?
The cannabis use disorder treatment market includes pharmaceutical products and therapeutic solutions categorized by type, treatment, end user, delivery channel.
How does FMI make the Cannabis Use Disorder Treatment forecast and check it?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified transaction data and checking it against global health databases and manufacturer disclosures.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Cannabis Use Disorder Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
